View in EDS

Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma.

Saved in:
Bibliographic Details
Title: Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma.
Authors: Le Saux O; 'Cancer Immune Surveillance and Therapeutic Targeting' Laboratory, Cancer Research Center of Lyon, INSERM 1052-CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France.; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France.; National Investigators Group for Ovarian and Breast Cancer Studies, Paris, France.; Department of Medical Oncology, Centre Léon Bérard, 69008, Lyon, France., Ardin M; 'Cancer Immune Surveillance and Therapeutic Targeting' Laboratory, Cancer Research Center of Lyon, INSERM 1052-CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France.; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France., Berthet J; 'Cancer Immune Surveillance and Therapeutic Targeting' Laboratory, Cancer Research Center of Lyon, INSERM 1052-CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France.; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France.; Lyon Immunotherapy for Cancer Laboratory (LICL), Cancer Research Center of Lyon, Centre Léon Bérard, 69008, Lyon, France., Barrin S; Lyon Immunotherapy for Cancer Laboratory (LICL), Cancer Research Center of Lyon, Centre Léon Bérard, 69008, Lyon, France., Bourhis M; Université Paris Cité, Inserm, PARCC, F-75015, Paris, France., Cinier J; 'Cancer Immune Surveillance and Therapeutic Targeting' Laboratory, Cancer Research Center of Lyon, INSERM 1052-CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France.; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France., Lounici Y; 'Cancer Immune Surveillance and Therapeutic Targeting' Laboratory, Cancer Research Center of Lyon, INSERM 1052-CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France.; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France., Treilleux I; Department of Anatomopathology, Centre Léon Bérard, 69008, Lyon, France., Just PA; Department of Anatomopathology, AP-HM, Marseille, France., Bataillon G; Department of Anatomopathology, University hospital of Toulouse, Toulouse, France., Savoye AM; National Investigators Group for Ovarian and Breast Cancer Studies, Paris, France.; Department of Medical Oncology, Institut Jean Godinot, Reims, France., Mouret-Reynier MA; National Investigators Group for Ovarian and Breast Cancer Studies, Paris, France.; Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France., Coquan E; National Investigators Group for Ovarian and Breast Cancer Studies, Paris, France.; Department of Medical Oncology, Centre François Baclesse, Caen, France., Derbel O; Department of Medical Oncology, Hôpital Privé Jean Mermoz, Lyon, France., Jeay L; Keen Eye Technologies-Paris, France, now Tribun Health, Paris, France., Bouizaguen S; Keen Eye Technologies-Paris, France, now Tribun Health, Paris, France., Labidi-Galy I; Department of Oncology, Hôpitaux universitaires de Genève, Faculty of Medecine, Center of Translational Research in Onco-Hematology, Swiss Cancer Center Leman, Geneva, Switzerland., Tabone-Eglinger S; Human Biological Resources, Centre Léon Bérard, 69008, Lyon, France., Ferrari A; Synergie Lyon Cancer, Gilles Thomas Bioinformatics Platform, Centre Léon Bérard, CEDEX 08, F-69373, Lyon, France., Thomas E; Synergie Lyon Cancer, Gilles Thomas Bioinformatics Platform, Centre Léon Bérard, CEDEX 08, F-69373, Lyon, France., Ménétrier-Caux C; 'Cancer Immune Surveillance and Therapeutic Targeting' Laboratory, Cancer Research Center of Lyon, INSERM 1052-CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France.; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France.; Lyon Immunotherapy for Cancer Laboratory (LICL), Cancer Research Center of Lyon, Centre Léon Bérard, 69008, Lyon, France., Tartour E; Université Paris Cité, Inserm, PARCC, F-75015, Paris, France., Galy-Fauroux I; Université Paris Cité, Inserm, PARCC, F-75015, Paris, France., Stern MH; Inserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.) Team, Institut Curie, PSL Research University, 75005, Paris, France., Terme M; Université Paris Cité, Inserm, PARCC, F-75015, Paris, France., Caux C; 'Cancer Immune Surveillance and Therapeutic Targeting' Laboratory, Cancer Research Center of Lyon, INSERM 1052-CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France.; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France.; Lyon Immunotherapy for Cancer Laboratory (LICL), Cancer Research Center of Lyon, Centre Léon Bérard, 69008, Lyon, France., Dubois B; 'Cancer Immune Surveillance and Therapeutic Targeting' Laboratory, Cancer Research Center of Lyon, INSERM 1052-CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France. bertrand.dubois@lyon.unicancer.fr.; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France. bertrand.dubois@lyon.unicancer.fr.; Lyon Immunotherapy for Cancer Laboratory (LICL), Cancer Research Center of Lyon, Centre Léon Bérard, 69008, Lyon, France. bertrand.dubois@lyon.unicancer.fr., Ray-Coquard I; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France. isabelle.ray-coquard@lyon.unicancer.fr.; National Investigators Group for Ovarian and Breast Cancer Studies, Paris, France. isabelle.ray-coquard@lyon.unicancer.fr.; Department of Medical Oncology, Centre Léon Bérard, 69008, Lyon, France. isabelle.ray-coquard@lyon.unicancer.fr.
Source: Nature communications [Nat Commun] 2024 Jul 16; Vol. 15 (1), pp. 5932. Date of Electronic Publication: 2024 Jul 16.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39013886
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Le+Saux+O%22">Le Saux O</searchLink>; 'Cancer Immune Surveillance and Therapeutic Targeting' Laboratory, Cancer Research Center of Lyon, INSERM 1052-CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France.; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France.; National Investigators Group for Ovarian and Breast Cancer Studies, Paris, France.; Department of Medical Oncology, Centre Léon Bérard, 69008, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Ardin+M%22">Ardin M</searchLink>; 'Cancer Immune Surveillance and Therapeutic Targeting' Laboratory, Cancer Research Center of Lyon, INSERM 1052-CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France.; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Berthet+J%22">Berthet J</searchLink>; 'Cancer Immune Surveillance and Therapeutic Targeting' Laboratory, Cancer Research Center of Lyon, INSERM 1052-CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France.; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France.; Lyon Immunotherapy for Cancer Laboratory (LICL), Cancer Research Center of Lyon, Centre Léon Bérard, 69008, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Barrin+S%22">Barrin S</searchLink>; Lyon Immunotherapy for Cancer Laboratory (LICL), Cancer Research Center of Lyon, Centre Léon Bérard, 69008, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Bourhis+M%22">Bourhis M</searchLink>; Université Paris Cité, Inserm, PARCC, F-75015, Paris, France.<br /><searchLink fieldCode="AU" term="%22Cinier+J%22">Cinier J</searchLink>; 'Cancer Immune Surveillance and Therapeutic Targeting' Laboratory, Cancer Research Center of Lyon, INSERM 1052-CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France.; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Lounici+Y%22">Lounici Y</searchLink>; 'Cancer Immune Surveillance and Therapeutic Targeting' Laboratory, Cancer Research Center of Lyon, INSERM 1052-CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France.; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Treilleux+I%22">Treilleux I</searchLink>; Department of Anatomopathology, Centre Léon Bérard, 69008, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Just+PA%22">Just PA</searchLink>; Department of Anatomopathology, AP-HM, Marseille, France.<br /><searchLink fieldCode="AU" term="%22Bataillon+G%22">Bataillon G</searchLink>; Department of Anatomopathology, University hospital of Toulouse, Toulouse, France.<br /><searchLink fieldCode="AU" term="%22Savoye+AM%22">Savoye AM</searchLink>; National Investigators Group for Ovarian and Breast Cancer Studies, Paris, France.; Department of Medical Oncology, Institut Jean Godinot, Reims, France.<br /><searchLink fieldCode="AU" term="%22Mouret-Reynier+MA%22">Mouret-Reynier MA</searchLink>; National Investigators Group for Ovarian and Breast Cancer Studies, Paris, France.; Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.<br /><searchLink fieldCode="AU" term="%22Coquan+E%22">Coquan E</searchLink>; National Investigators Group for Ovarian and Breast Cancer Studies, Paris, France.; Department of Medical Oncology, Centre François Baclesse, Caen, France.<br /><searchLink fieldCode="AU" term="%22Derbel+O%22">Derbel O</searchLink>; Department of Medical Oncology, Hôpital Privé Jean Mermoz, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Jeay+L%22">Jeay L</searchLink>; Keen Eye Technologies-Paris, France, now Tribun Health, Paris, France.<br /><searchLink fieldCode="AU" term="%22Bouizaguen+S%22">Bouizaguen S</searchLink>; Keen Eye Technologies-Paris, France, now Tribun Health, Paris, France.<br /><searchLink fieldCode="AU" term="%22Labidi-Galy+I%22">Labidi-Galy I</searchLink>; Department of Oncology, Hôpitaux universitaires de Genève, Faculty of Medecine, Center of Translational Research in Onco-Hematology, Swiss Cancer Center Leman, Geneva, Switzerland.<br /><searchLink fieldCode="AU" term="%22Tabone-Eglinger+S%22">Tabone-Eglinger S</searchLink>; Human Biological Resources, Centre Léon Bérard, 69008, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Ferrari+A%22">Ferrari A</searchLink>; Synergie Lyon Cancer, Gilles Thomas Bioinformatics Platform, Centre Léon Bérard, CEDEX 08, F-69373, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Thomas+E%22">Thomas E</searchLink>; Synergie Lyon Cancer, Gilles Thomas Bioinformatics Platform, Centre Léon Bérard, CEDEX 08, F-69373, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Ménétrier-Caux+C%22">Ménétrier-Caux C</searchLink>; 'Cancer Immune Surveillance and Therapeutic Targeting' Laboratory, Cancer Research Center of Lyon, INSERM 1052-CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France.; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France.; Lyon Immunotherapy for Cancer Laboratory (LICL), Cancer Research Center of Lyon, Centre Léon Bérard, 69008, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Tartour+E%22">Tartour E</searchLink>; Université Paris Cité, Inserm, PARCC, F-75015, Paris, France.<br /><searchLink fieldCode="AU" term="%22Galy-Fauroux+I%22">Galy-Fauroux I</searchLink>; Université Paris Cité, Inserm, PARCC, F-75015, Paris, France.<br /><searchLink fieldCode="AU" term="%22Stern+MH%22">Stern MH</searchLink>; Inserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.) Team, Institut Curie, PSL Research University, 75005, Paris, France.<br /><searchLink fieldCode="AU" term="%22Terme+M%22">Terme M</searchLink>; Université Paris Cité, Inserm, PARCC, F-75015, Paris, France.<br /><searchLink fieldCode="AU" term="%22Caux+C%22">Caux C</searchLink>; 'Cancer Immune Surveillance and Therapeutic Targeting' Laboratory, Cancer Research Center of Lyon, INSERM 1052-CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France.; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France.; Lyon Immunotherapy for Cancer Laboratory (LICL), Cancer Research Center of Lyon, Centre Léon Bérard, 69008, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Dubois+B%22">Dubois B</searchLink>; 'Cancer Immune Surveillance and Therapeutic Targeting' Laboratory, Cancer Research Center of Lyon, INSERM 1052-CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France. bertrand.dubois@lyon.unicancer.fr.; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France. bertrand.dubois@lyon.unicancer.fr.; Lyon Immunotherapy for Cancer Laboratory (LICL), Cancer Research Center of Lyon, Centre Léon Bérard, 69008, Lyon, France. bertrand.dubois@lyon.unicancer.fr.<br /><searchLink fieldCode="AU" term="%22Ray-Coquard+I%22">Ray-Coquard I</searchLink>; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France. isabelle.ray-coquard@lyon.unicancer.fr.; National Investigators Group for Ovarian and Breast Cancer Studies, Paris, France. isabelle.ray-coquard@lyon.unicancer.fr.; Department of Medical Oncology, Centre Léon Bérard, 69008, Lyon, France. isabelle.ray-coquard@lyon.unicancer.fr.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101528555%22">Nature communications</searchLink> [Nat Commun] 2024 Jul 16; Vol. 15 (1), pp. 5932. <i>Date of Electronic Publication: </i>2024 Jul 16.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101528555 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2041-1723 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220411723%22">20411723 </searchLink><i>NLM ISO Abbreviation: </i>Nat Commun <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39013886
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41467-024-47000-5
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 5932
    Titles:
      – TitleFull: Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Le Saux O
      – PersonEntity:
          Name:
            NameFull: Ardin M
      – PersonEntity:
          Name:
            NameFull: Berthet J
      – PersonEntity:
          Name:
            NameFull: Barrin S
      – PersonEntity:
          Name:
            NameFull: Bourhis M
      – PersonEntity:
          Name:
            NameFull: Cinier J
      – PersonEntity:
          Name:
            NameFull: Lounici Y
      – PersonEntity:
          Name:
            NameFull: Treilleux I
      – PersonEntity:
          Name:
            NameFull: Just PA
      – PersonEntity:
          Name:
            NameFull: Bataillon G
      – PersonEntity:
          Name:
            NameFull: Savoye AM
      – PersonEntity:
          Name:
            NameFull: Mouret-Reynier MA
      – PersonEntity:
          Name:
            NameFull: Coquan E
      – PersonEntity:
          Name:
            NameFull: Derbel O
      – PersonEntity:
          Name:
            NameFull: Jeay L
      – PersonEntity:
          Name:
            NameFull: Bouizaguen S
      – PersonEntity:
          Name:
            NameFull: Labidi-Galy I
      – PersonEntity:
          Name:
            NameFull: Tabone-Eglinger S
      – PersonEntity:
          Name:
            NameFull: Ferrari A
      – PersonEntity:
          Name:
            NameFull: Thomas E
      – PersonEntity:
          Name:
            NameFull: Ménétrier-Caux C
      – PersonEntity:
          Name:
            NameFull: Tartour E
      – PersonEntity:
          Name:
            NameFull: Galy-Fauroux I
      – PersonEntity:
          Name:
            NameFull: Stern MH
      – PersonEntity:
          Name:
            NameFull: Terme M
      – PersonEntity:
          Name:
            NameFull: Caux C
      – PersonEntity:
          Name:
            NameFull: Dubois B
      – PersonEntity:
          Name:
            NameFull: Ray-Coquard I
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 16
              M: 07
              Text: 2024 Jul 16
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 2041-1723
          Numbering:
            – Type: volume
              Value: 15
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Nature communications
              Type: main
ResultId 1